logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Begoña Bermejo

biomedical research institute incliva
H指数:41
被引数:6,634

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

HER2阳性早期乳腺癌化疗降级治疗的5年结局及PHERGain随机II期试验中的探索性循环肿瘤DNA分析

Nature Medicine
IF50
2026-10-290
OAAI
José Manuel Pérez-García; Javier Cortés; Manuel Ruiz-Borrego; Agostina Stradella; Begoña Bermejo; Santiago Escrivá-de-Romaní; Cristina Reboredo; Cinta Albacar; Noelia Martínez-Jáñez; Vega Iranzo; Nuria Ribelles; Florence Dalenc; Aleix Prat; Peter Schmid; Geraldine Gebhart; Frederik Marmé; Serena Di Cosimo; Sofia Braga; Marco Colleoni; Gabriele Antonarelli; Giulia Notini; Maria Gion; Juan José García-Mosquera; Lucia Sanz; Elena Martinez-Garcia; Alba Meya; Derek Dustin; Ana Amaya-Garrido; Jose Antonio Guerrero-Martínez; Daniel Alcalá-López; Jose Rodríguez-Morató; Leonardo Mina; Mario Mancino; Antonio Llombart-Cussac
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples

乳腺组织特异性的表观遗传时钟可提供准确的年龄预测，并揭示肿瘤邻近组织和肿瘤样本中年龄与DNA甲基化的去相关性

Epigenetics
IF3.2
2026-09-110
OAAI
Leonardo D. Garma; Sonia Pernas; Bartomeu Fullana; Andrea Vethencourt; David Vicente Baz; Teresa García Manrique; Rosario García Campelo; Cristina Reboredo; Josefa Terrasa; Antonia Perello; Ramón Colomer; Desirée Jiménez; Ruth Vera García; Susana de la Cruz Sánchez; Begoña Bermejo; Marta Tapia; Santiago González Santiago; Miguel Quintela-Fandino
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+/HER2− metastatic breast cancer: a translational analysis of the GEICAM/2013-02 PEARL trial

动态胸苷激酶活性独立捕获治疗特异性的生物学反应，并与内分泌耐药的HR+/HER2−转移性乳腺癌的结局独立相关：GEICAM/2013-02 PEARL试验的转化分析

European Journal of Cancer
IF7.1
2026-05-250
OAAI
Ángel Guerrero-Zotano; Miguel Gil-Gil; Amy Williams; Manuel Ruiz-Borrego; Hanna Ritzén; Eva María Ciruelos; Montserrat Muñoz; Begoña Bermejo; Mireia Margelí; Antonio Antón; Zsuzsanna Kahan; Tibor Csöszi; Laura Murillo; Serafín Morales Murillo; Istvan Lang; Cristina Reboredo Rendo; Emilio Alba; Pablo Álvarez; Juan de la Haba-Rodriguez; Isabel Álvarez
Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies

激素受体阳性/HER2阴性早期乳腺癌患者按复发风险分组的结局：聚焦于中危组：GEICAM研究的回顾性分析

Breast Cancer Research
IF5.6
2026-05-250
OAAI
Sonia Servitja; Eva Carrasco; Raquel Andrés; Álvaro Rodríguez-Lescure; Miguel Martín; Manuel Ruiz-Borrego; Ángel Guerrero; Begoña Bermejo; Antonio Antón; Montserrat Muñoz; Mireia Margeli; Isabel Álvarez; Luis Antonio Fernández; Jose Ponce; Josefina Cruz; Purificación Martínez; Sara López-Tarruella; Margarita Amenedo; Andrea Blasco; Óscar Polonio; Miguel Gil-Gil
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆

一种基于曲妥珠单抗–帕妥珠单抗和T-DM1的病理反应适应策略在HER2阳性早期乳腺癌中的应用：PHERGain-2研究☆

Annals of Oncology
IF65.4
2026-05-060
OA
L. Garrigós; M. Ruiz-Borrego; J.M. Pérez-García; A. Guerrero-Zotano; A. Cortés-Salgado; S. Kuemmel; M. Colleoni; C. Reboredo-Rendo; B. Bermejo; I. Blancas; J. Gavila; A. Fabi; C. Morales; A. Stradella; V. Carañana; E. Martínez-de Dueñas; C. Albacar; O. Ballesteros-Cidras; G. Martrat; S. Iacobucci
Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer

成纤维细胞活化蛋白α靶向纳米颗粒用于三阴性乳腺癌的肿瘤微环境重塑和抗肿瘤治疗

Biomaterials Research
IF9.6
2026-04-010
PRE
Lameirinhas, Ana; Diez, Paula; Hicke, Francisco J.; Agreda-Roca, Anna; Torres-Ruiz, Sandra; Sanchez-Serrano, Paloma; Tapia, Marta; Lluch, Ana; Bermejo, Begona; Cejalvo, Juan Miguel; Martinez-Manez, Ramon; Eroles, Pilar; Garrido-Cano, Iris
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study

tiragolumab、atezolizumab联合化疗在早期或PD-L1阳性晚期三阴性乳腺癌中的安全性与有效性：一项 Ib 期研究

ESMO Open
IF8.3
2025-11-250
OAAI
S. Kuemmel; K.H. Jung; L. Andrade; D. Assad-Suzuki; L. de la Cruz Merino; R. Freitas-Junior; R. Hegg; C.-S. Huang; H. Martin; A. Schneeweiss; M. Dieterich; A. Nguyen Duc; Y. Feng; R. Meng; A. Swat; A. Seiller; B. Bermejo; E.P. Hamilton
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

靶向ER、FGFR和CDK4/6的协同临床试验，用于具有FGFR变异的耐药性激素阳性乳腺癌

npj Precision Oncology
IF8
2025-11-070
OAAI
Noelia Martinez-Jañez; José Ángel García-Saenz; Sonia Pernas; Begoña Bermejo; Serafín Morales; Juan Guerra; Jorge Silva; Luis Manso; Eva Ciruelos; Pablo Tolosa; Rodrigo Sánchez-Bayona; Manuel Alva; Silvia Calabuig-Fariñas; Sandra Gallach; Laura Muinelo-Romay; Elena Piñeiro-Yáñez; Eduardo Caleiras; Maria J. Bueno; Silvana Mouron; Miguel Quintela-Fandino
Comparing [18F]FDG–positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial☆

比较[18F]FDG-正电子发射断层扫描与乳腺磁共振成像预测HER2阳性早期乳腺癌患者病理完全缓解和3年侵袭性无病生存率的比较：PHERGain试验的非计划探索性分析☆

ESMO Open
IF8.3
2025-11-060
OAAI
J.J. García-Mosquera; J.M. Pérez-García; M. Ruiz-Borrego; A. Stradella; B. Bermejo; S. Escrivá-de-Romaní; L. Calvo Martínez; G. Gebhart; K. Kerrou; M. Gion; G. Antonarelli; S. Santasusagna Canal; J. Rodríguez-Morato; L. Mina; M. Sampayo-Cordero; A. Llombart-Cussac; J. Cortés
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer

肿瘤特异性主要组织相容性-II表达预测三阴性乳腺癌中阿替利珠单抗联合化疗的病理完全缓解

npj Breast Cancer
IF7.6
2025-09-290
OAAI
Justin M. Balko; Luca Licata; Xiao Qian Wang; Matteo Dugo; Chiun-Sheng Huang; Daniel Egle; Begoña Bermejo; Claudio Zamagni; Marc Thill; Antonio Anton; Stefania Russo; Elena Sevillano; Eva Maria Ciruelos; Richard Greil; Vladimir Semiglazov; Marco Colleoni; Catherine M. Kelly; Gabriella Mariani; Lucia Del Mastro; Stefania Zambelli; Giulia Viale; Maurizio Callari; Giuseppe Viale; Lajos Pusztai; Luca Gianni; H. Raza Ali; Giampaolo Bianchini
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

中间终点作为长期结局的替代指标在乳腺癌辅助化疗试验中的应用

ONCOLOGIST
IF4.2
2025-09-010
OAAI
Blasco, Andrea; Lopez-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martin, Miguel; Bermejo, Begona; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; Garcia-Saenz, Jose A.; Chan, Arlene; Guerrero-Zotano, Angel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesus; Slamon, Dennis
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak

TIM3⁺乳腺癌细胞在微转移爆发期间促进免疫逃逸

Cancer Cell
IF44.5
2025-07-100
OAAI
Catalina Rozalén; Irene Sangrador; Silvia Avalle; Sandra Blasco-Benito; Panagiota Tzortzi; María Sanz-Flores; José Ángel Palomeque; Pau Torren-Duran; Mariona Dalmau; Helena Brunel; Albert Coll-Manzano; Iván Pérez-Núñez; Tamara Martos; Sonia Servitja; Sandra Pérez-Buira; José Ignacio Chacón; Ángel Guerrero-Zotano; Eduardo Martínez de Dueñas; Yolanda Guillén; Laura Comerma; Begoña Bermejo; Anna Bigas; María Casanova-Acebes; Anna Alemany; Federico Rojo; Joan Albanell; Toni Celià-Terrassa
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2025-04-100
OAAI
Garcia-Saenz, Jose A.; Spera, Gonzalo; Pollan, Marina; Bermejo, Begona; Ruiz-Borrego, Manuel; Chan, Arlene; Martin, Miguel; Guerrero-Zotano, Angel; Calvo, Lourdes; Rodriguez-Lescure, Alvaro; Marin, Maria; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Oscar; Bezares, Susana; Slamon, Dennis
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

回顾性分析以验证El Álamo IV登记研究和GEICAM辅助研究中患者的CTS5。

ONCOLOGIST
IF4.2
2025-04-040
OA
Lopez-Tarruella, Sara; Pollan, Marina; Carrasco, Eva; Andres, Raquel; Martin, Miguel; Servitja, Sonia; Bermejo, Begona; Anton, Antonio; Guerrero-Zotano, Angel; Munoz, Montserrat; Fernandez, Luis; del Prado, Purificacion Martinez; Alvarez, Isabel; Calvo, Lourdes; Rodriguez-Lescure, Alvaro; Marin, Maria; Ruiz-Borrego, Manuel; Herranz, Jesus; Polonio, Oscar; Adrover, Encarna; Moreno, Diana
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study
NPJ BREAST CANCER
IF7.6
2025-02-080
OAAI
Pena-Enriquez, Regina; Bermejo, Begona; Pollan, Marina; Diaz-Chacon, Alejandra; Gilarranz, Yolanda Jerez; Lorenzo, Jose J. Ponce; Aramburo, Antonio Fernandez; de Ibarguen, Blanca Cantos Sanchez; Bertran, Ana Santaballa; Galve-Calvo, Elena; Jimenez-Arranz, Alvaro; Fernandez, Yolanda; Perez, Maria Eva; de la Cruz, Susana; Anton-Torres, Antonio; Moreno, Fernando; Vidal-Losada, Maria Jesus; Lopez-Ceballos, Maria Helena; Blancas, Isabel; Echarri, Maria Jose; Rincon, Raul; Caballero, Rosalia; Guerrero-Zotano, Angel; Guil-Luna, Silvia; de la Haba-rodriguez, Juan
Gestational breast cancer: distinctive molecular and clinico-epidemiological features
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
IF3.6
2024-11-081
OAAI
de la Haba-Rodriguez, J. R.; Minguez, P.; Rojo, F.; Martin, M.; Alba, E.; Servitja, S.; Prat, A.; Perez-Fidalgo, J. A.; Gavila, J.; Morales, C.; Rodriguez-Lescure, A.; Herrero, C.; Pena-Enriquez, R.; Herranz, J.; Hernando, C.; Hernandez-Blanquisett, A.; Guil-Luna, S.; Martinez, M. T.; Blanch, S.; Caballero, R.; Martin, N.; Pollan, M.; Guerrero-Zotano, A.; Bermejo, B.
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

Olaparib联合曲妥珠单抗治疗生殖系BRCA1/2突变的HER2-positive晚期乳腺癌患者: OPHELIA 2期研究

BREAST
IF7.9
2024-10-010
OAAI
Ales-Martinez, Jose Enrique; Balmana, Judith; Sanchez-Rovira, Pedro; Bofill, Francisco Javier Salvador; Saenz, Jose Angel Garcia; Pimentel, Isabel; Morales, Serafin; Fernandez-Abad, Maria; Martinez, Ainhara Lahuerta; Ferrer, Neus; Zamora, Pilar; Bermejo, Begona; Diaz-Redondo, Tamara; Lopez-Ceballos, Maria Helena; Galan, Maria; Perez-Escuredo, Jhudit; Calabuig, Laura; Sampayo, Miguel; Perez-Garcia, Jose Manuel; Cortes, Javier; Llombart-Cussac, Antonio
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
ESMO OPEN
IF8.3
2024-10-010
OAAI
Guerrero-Zotano, A.; Perez-Garcia, J. M.; Ruiz-Borrego, M.; Bermejo, B.; Gil-Gil, M.; de la Haba, J.; Conejo, E. Alba; Quiroga, V; Caranana, V; Urruticoechea, A.; Morales, S.; Bellet, M.; Anton, A.; Fernandez-Abad, M.; Sanchez-Rovira, P.; Calabuig, L.; Perez-Escuredo, J.; Sampayo-Cordero, M.; Cortes, J.; Llombart-Cussac, A.

研究方向

暂未获取到该数据
A
Antonio Llombart‐Cussac
H 指数:59论文数:698被引数:1.6万
J
Javier Cortés
H 指数:113论文数:1,481被引数:6.8万
A
Aňa Lluch
H 指数:72论文数:794被引数:2.6万
E
Eva Ciruelos
H 指数:54论文数:695被引数:1.9万
S
Serafín Morales
H 指数:30论文数:338被引数:6,684
J
Juan Miguel Cejalvo
H 指数:26论文数:243被引数:3,371
A
Aleix Prat
H 指数:92论文数:1,351被引数:3.6万
M
Montserrat Muñoz-Mateu
H 指数:50论文数:620被引数:9,874
O
Octavio Burgués
H 指数:25论文数:127被引数:2,127
M
Mafalda Oliveira
H 指数:48论文数:564被引数:1.3万